Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · STAAR Surgical (STAA)

STAAR Surgical names Warren Foust president and CEO, effective August 4, 2026

Neutral Impact 4 of 5 leadership Written later

STAAR Surgical's board appointed Warren Foust, previously its President and COO, as President, CEO and a board member, effective August 4, 2026. Deborah Andrews, who had been Interim Co-CEO since February 2026, stays as Chief Financial Officer and was named Executive Vice President. The filing also details large equity grants to both executives, which will dilute shareholders as they vest.

Key points

  • Warren Foust has been President and COO since March 2025 and joined STAAR in April 2023; his base salary is $730,000 annually.
  • Foust's CEO grant includes 22,493 time-vesting RSUs, 40,471 time-vesting options and 131,830 performance-vesting options tied to $50, $75 and $100 share price hurdles.
  • Deborah Andrews will cease as Interim Co-CEO, remain CFO and receive an option grant of 8,952 shares, 29,159 performance options and 4,975 RSUs.
  • The filing furnishes a press release dated August 4, 2026 as Exhibit 99.1.

The filing

CompanySTAAR Surgical (STAA)
Form8-K, current report
Filed with the SECAug 6, 2026, 11:04 AM ET
Accession number0001193125-26-337197

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.